OTC: NURPF - Neuren Pharmaceuticals Limited

半年間の収益性: -21.88%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Neuren Pharmaceuticals Limited

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares.

さらに詳しく
Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.neurenpharma.com
Цена ао 7.25
1日あたりの価格変動: 0% (7.25)
週ごとの価格変動: -6.58% (7.7607)
月ごとの料金変更: -13.28% (8.36)
3ヶ月間の価格変動: -9.38% (8)
半年間の価格変動: -21.88% (9.28)
年間の価格変動: -48.21% (14)
3年間の価格推移: +137.35% (3.0545)
5年間の価格推移: +279.58% (1.91)
年初からの価格変動: -11.8% (8.22)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 12.7 1
P/BV 14.35 1
P/E 18.75 7
EV/EBITDA 14.7 7
合計: 5.63

効率

名前 意味 学年
ROA, % 63.35 10
ROE, % 76.55 10
合計: 8.33

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA 0 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 46756.97 10
収益性 Ebitda, % -1821.79 0
収益性 EPS, % -2025.02 0
合計: 2
さらに詳しく

機関 音量 共有, %
Vanguard International Stock Index-Total Intl Stock Indx 1480133 1.16
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 877162 0.69
iShares Core MSCI EAFE ETF 652944 0.51
iShares MSCI EAFE Small Cap ETF 436465 0.34
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 403572 0.32
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 215442 0.17
iShares Core MSCI Total International Stock ETF 140892 0.11
Vanguard International Stock Index-Pacific Stock Index 128668 0.1
College Retirement Equities Fund-Stock Account 85378 0.07
SEI Institutional International Tr-International Equity 71485 0.06



スーパーバイザー 役職 支払い 生年
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director 714.28k
Ms. Lauren Frazer C.A. CFO & Company Secretary N/A
Mr. Lawrence Glass BA (Biology) Chief Science Officer N/A
Mr. Gerry Zhao Vice President of Corporate Development N/A
Dr. Liza A. Squires M.D. Chief Medical Officer N/A

住所: Australia, Camberwell, 697 Burke Road - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.neurenpharma.com